United States Bio-Pharma Logistics Market Size, Share, Growth Trends, and Forecast (2024-2031): Valued at US$ 109 Billion in 2024, Expected to Reach US$ 180 Billion by 2031, Growing at a CAGR of 7.2%

Market Size and Growth

The Global Bio-Pharma Logistics Market was valued at US$ 113.6 billion in 2023 and is projected to reach US$ 174.2 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/bio-pharma-logistics-market?juli

United States: Recent Industry Developments

✅In November 2025, Cencora (formerly AmerisourceBergen) announced a US$ 1 billion investment to expand its U.S. cold-chain and specialty drug distribution network, addressing the rising demand for biologics requiring advanced logistics.

✅Cardinal Health revealed plans for a new 230,000 sq ft pharmaceutical distribution center in Indianapolis, aimed at supporting specialty biologics shipments and integrating automation, expected to be operational by late 2027.

✅DHL Supply Chain expanded its biopharma logistics capabilities across major U.S. hubs with advanced temperature-controlled storage and AI-driven shipment monitoring solutions.

Japan: Recent Industry Developments

✅The Japan biopharma logistics market was valued at US$ 6.34 billion in 2024 and is projected to reach US$ 12.21 billion by 2033, driven by increasing biologics and gene therapy volumes.

✅The Pharmaceuticals and Medical Devices Agency (PMDA) introduced updated Good Distribution Practice (GDP) guidelines, encouraging the use of blockchain-based data integrity and real-time tracking for biologics.

✅Japanese logistics providers are investing in smart cold-chain warehouses and IoT-enabled temperature control systems to meet rising demand from precision medicine and regenerative therapy sectors.

Market Segmentation Analysis

By Type of Operations
Cold-Chain Logistics:
This segment dominates the market due to the increasing demand for temperature-sensitive pharmaceuticals, biologics, and vaccines. Growing investments in cold storage infrastructure and IoT-based monitoring systems ensure product integrity during transportation.

Non-Cold Chain Logistics:
Encompasses the transport of conventional drugs and medical devices that do not require temperature-controlled storage. Although smaller in share, this segment continues to grow steadily due to the expansion of generic drug distribution networks.

By Application
Air Shipping:
The largest segment, driven by the need for fast, long-distance transport of biologics, vaccines, and cell therapies. Air freight providers are adopting temperature-controlled containers and digital tracking systems to enhance reliability.

Sea Shipping:
Gaining traction for cost-effective large-volume transport. Innovations in reefer containers and real-time temperature monitoring support the safe movement of bio-pharma products across regions.

Road Shipping:
A vital link in last-mile delivery and regional distribution networks. Growth is supported by refrigerated vehicles and smart logistics systems ensuring temperature compliance.

Rail Shipping:
Emerging as a sustainable alternative for intercontinental transport in Europe and Asia. Advancements in refrigerated rail containers and green logistics initiatives are boosting adoption.

COVID-19 Impact Analysis

With the COVID-19 pandemic, the trade of conventional and over-the-counter (OTC) drugs has increased globally. As governments, industry and other entities begin COVID-19 vaccine distribution efforts worldwide, cold chain management has emerged as a crucial factor for ensuring vaccine safety and effectiveness. Cold chain management entails maintaining refrigeration levels for highly temperature-sensitive coronavirus vaccines across manufacturing, storage, transportation and distribution processes.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bio-pharma-logistics-market

Key Players Analysis

1️⃣ Deutsche Post DHL Group (Germany)
Estimated Revenue (2023): US$ 96 billion
Market Role: Global leader in bio-pharma logistics with specialized cold chain services under DHL Life Sciences & Healthcare.
Core Offerings: Temperature-controlled warehousing, clinical trial logistics, and real-time monitoring through DHL SmartSensor.
Regional Focus: Strong presence in Europe and North America.
Market Share (Global Bio-Pharma Logistics): 15-17%

2️⃣ Kuehne + Nagel International AG (Switzerland)
Estimated Revenue (2023): US$ 42 billion
Market Role: Major provider of cold-chain transportation solutions for vaccines and biologics.
Core Offerings: KN PharmaChain a dedicated logistics platform ensuring real-time temperature tracking and compliance.
Regional Focus: Europe, Asia-Pacific, and North America.
Market Share: 10-12%

3️⃣ DB Schenker (Germany)
Estimated Revenue (2023): US$ 25 billion
Market Role: Offers multimodal logistics solutions for pharmaceutical and biotech companies.
Core Offerings: GDP-compliant storage, air/road/sea integrated supply chains, and AI-based route optimization.
Regional Focus: Europe, North America, and emerging APAC markets.
Market Share: 7-8%

4️⃣ FedEx Corporation (USA)
Estimated Revenue (2023): US$ 88 billion
Market Role: A top logistics provider with its FedEx HealthCare Priority and Marken subsidiary specializing in clinical trial supply chain management.
Core Offerings: End-to-end cold-chain logistics, biologics shipment, and time-sensitive drug delivery.
Regional Focus: Strong footprint in North America, Japan, and Europe.
Market Share: 13-15%

5️⃣ United Parcel Service (UPS) / Marken (USA)
Estimated Revenue (2023): US$ 91 billion (UPS Global)
Market Role: Through its subsidiary Marken, UPS dominates global clinical trial logistics and biologic sample management.
Core Offerings: Personalized medicine logistics, cell & gene therapy supply chains, and cold-chain packaging.
Regional Focus: North America, Europe, and Asia-Pacific.
Market Share: 10-11%

6️⃣ Agility Logistics (Kuwait)
Estimated Revenue (2023): US$ 7 billion
Market Role: Focused on healthcare logistics with a growing network across Asia and the Middle East.
Core Offerings: Cold storage facilities, air and sea freight solutions, and digital supply chain visibility.
Market Share: 4-5%

7️⃣ DSV A/S (Denmark)
Estimated Revenue (2023): US$ 35 billion
Market Role: Provides comprehensive pharmaceutical logistics services under DSV Healthcare Solutions.
Core Offerings: Real-time temperature control, digital documentation, and multimodal connectivity.
Regional Focus: Europe, North America, and Asia.
Market Share: 6-7%

8️⃣ Mainfreight Ltd (New Zealand)
Estimated Revenue (2023): US$ 4 billion
Market Role: Expanding presence in Asia-Pacific's pharmaceutical transport sector.
Core Offerings: Temperature-controlled freight and regional distribution.
Market Share: 2-3%

9️⃣ CEVA Logistics (France)
Estimated Revenue (2023): ~US$ 17 billion
Market Role: Offers advanced healthcare logistics through CEVA FORPATIENTS initiative.
Core Offerings: End-to-end biologics logistics and clinical trial management.
Regional Focus: Europe and North America.

Market Share: 5-6%
10️⃣ Panalpina World Transport (Switzerland, now part of DSV)
Merged with DSV to strengthen pharmaceutical logistics capabilities, enhancing the company's reach in cold chain air freight.

Get Customized Report as per your Business Requirements: https://www.datamintelligence.com/customize/bio-pharma-logistics-market?juli

Regional Insights

1️⃣ North America
Market Value (2024): US$ 36.8 billion
Forecast Value (2031): US$ 58.2 billion
CAGR (2024-2031): 6.8%
Overview:
North America remains the largest market for bio-pharma logistics due to the high concentration of pharmaceutical and biotech manufacturers in the U.S. and Canada. The region benefits from advanced healthcare infrastructure, widespread adoption of temperature-controlled logistics systems, and strong regulatory compliance (FDA, GDP).
U.S.: Dominates regional share owing to strong clinical trial networks and leading cold-chain innovations by FedEx, UPS (Marken), and DHL.
Canada: Focused on expanding biopharmaceutical production and efficient vaccine distribution channels post-COVID-19.

2️⃣ Europe
Market Value (2024): US$ 29.5 billion
Forecast Value (2031): US$ 45.6 billion
CAGR (2024-2031): 6.5%
Overview:
Europe is a mature and regulated market, driven by demand for temperature-sensitive biologics and growing biopharma production hubs in Germany, Switzerland, and the UK. Companies like Kuehne + Nagel, DB Schenker, and CEVA Logistics have strengthened cold-chain capabilities to comply with EU GDP standards.
The European Medicines Agency (EMA) supports harmonized cold-chain handling, ensuring high logistics reliability.

3️⃣ Asia-Pacific (APAC)
Market Value (2024): US$ 27.4 billion
Forecast Value (2031): US$ 50.9 billion
CAGR (2024-2031): 8.9% (Fastest growing region)
Overview:
Rapid expansion of the biopharmaceutical and vaccine production sector is driving demand for advanced logistics solutions in countries like Japan, China, South Korea, and India.
Japan: A key logistics hub with strong GDP-compliant cold-chain facilities, supported by advanced technology and partnerships between global and local logistics players such as Yamato and FedEx.
India: Witnessing heavy investment in cold storage infrastructure and feedstock manufacturing; Cargill and DHL are expanding bio-pharma logistics operations.
Government initiatives promoting biologics and clinical research are fueling growth.

4️⃣ Latin America
Market Value (2024): US$ 8.7 billion
Forecast Value (2031): US$ 14.6 billion
CAGR (2024-2031): 7.1%
Overview:
Growth in Brazil and Mexico is driven by rising vaccine imports, expansion of biologics R&D, and greater integration with North American cold-chain networks. However, the region still faces infrastructure and regulatory challenges that limit efficiency in temperature-sensitive supply chains.

5️⃣ Middle East & Africa (MEA)
Market Value (2024): US$ 6.4 billion
Forecast Value (2031): US$ 10.8 billion
CAGR (2024-2031): 7.4%
Overview:
MEA's bio-pharma logistics market is gaining traction due to healthcare modernization efforts and vaccine distribution initiatives.
UAE and Saudi Arabia serve as regional logistics hubs with major investments in air freight and temperature-controlled warehouses.
South Africa remains a key import destination for pharmaceutical products.

Future Outlook

The global bio-pharma logistics market is projected to witness steady and sustained expansion, driven by the rising global demand for biologics, vaccines, and precision medicines that require stringent temperature-controlled handling. The market, valued at approximately US$ 109 billion in 2024, is anticipated to reach around US$ 180 billion by 2031, growing at a CAGR of 7.2% during the forecast period.

Conclusion

The Global Bio-Pharma Logistics Market is evolving as a critical backbone of the pharmaceutical and healthcare ecosystem. With rising demand for temperature-sensitive biologics, vaccines, and specialty drugs, the market is witnessing rapid innovation in cold-chain management, digital tracking, and compliance-driven transport solutions.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?jk

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.